ECG abnormarmalities in first visit of diabetic patients in Al Sammawah Diabetic Center:cohort study Muthanna Medical Journal

To read the full-text of this research, you can request a copy directly from the author.

No full-text available

Request Full-text Paper PDF

To read the full-text of this research,
you can request a copy directly from the author.

... T2DM one of the worldwide diseases about 425 million people have diabetes and expected that increasing to 642 million in 2040 (Ogurtsova et al, 2017;ADA, 2019). In the Iraqi population about 1.2 million registered cases of diabetes in 2015 (Hallawee et al, 2017). Cardiovascular disease is very common among people with diabetes, in fact, it can lead to death the most important of these diseases are CAD (Naito and Miyauchi, 2017). ...
Full-text available
Glucagon-like peptide 1 bestows protective effects upon the cardiovascular system through direct cardiovascular interactions or by improvements to metabolic function. Both these effects to be at least partly mediated by the GLP-1 receptor (GLP-1R). This study was carried out to investigate whether polymorphisms in the GLP-1R gene affect the risk of cardiovascular disease in Iraqi Patients with Type 2 Diabetic under studyAnd the association of the diabetic disease with biochemical markers including, fasting blood glucose (FBG) and glycated hemoglobin (HbA1c) in blood serum in addition to other clinical markers as lipid profile including Triglycerides (TG), Total cholesterol (TC), high density lipoproteins (HDL), low density lipoproteins (LDL)in serum samples of Iraqi patients with type 2 diabetic and healthy controls. Genetic polymorphism was studied in the variation site rs10305492ý and rs4714210 SNPs on the GLP1R gene. First of all, genomic DNA was extracted from blood samples for T2DM patients and healthy controls with a concentration ranged between 200-400 ìg/ml and purity ranged between 1.5-2.0, then Primer sets (GL1 and GL2) cover the area surrounding the location of rs10305492ý and rs4714210 SNPs on the GLP1R gene was amplified. Results of electrophoresis on 2% agarose gel for the amplified products showed that there are amplified fragments with a molecular size 939 bp and 854 bp were obtained. Results of sequencing for the amplified fragment revealed that the SNP variation rs10305492 was not found in both patient and control. Nevertheless, a new possible variation was observed in a number of patients where (G) was replaced by (A) in location 29.990 bp of the GLP1R gene. Both homozygous and heterozygous mutations exhibited a non-significance association with the risk of CAD. Results also showed that, the rs4714210 (A>G) were significant differences between cases and controls. The allele (G) increased risk for CAD (OR =8.61, 95% CI = 2.44-30.42, p=0.0008), also the mutant homozygous and heterozygous consider a risk factor for CAD (OR =10.4, 95% CI = 2.1=41.44.797, p = 0.002), (OR =22.62, 95% CI = 1.17-436.44, p = 0.039). Furthermore, sequencing the area surrounding each SNP location has revealed a new possible variation in which (A) base is replaced by (G) base in location (39,139bp) and (38,929 bp) of GLP1R gene sequence. 39 patients (86.7%) have demonstrated this variation which suggests a valuable indication of the appearance of these alterations in GLP1R gene in T2DM patients.
ResearchGate has not been able to resolve any references for this publication.